A long-term survival case of pancreatic cancer with hepatic metastasis after pancreaticoduodenectomy successfully treated by S-1 and gemcitabine combination chemotherapy

Hiromitsu Hoshino, Yutaka Takeda, Hiroaki Nagano, Shoji Nakamori, Shogo Kobayashi, Hidetoshi Eguchi, Shigeru Marubashi, Masahiro Tanemura, Toru Kitagawa, Koji Umeshita, Morito Monden, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Gemcitabine monotherapy is accepted as a standard first-line treatment for locally advanced unresectable or metastatic pancreatic cancer. On another front, S-1 and gemcitabine combination chemotherapy is challenging but promising. We report a long-term survival case of pancreatic cancer with hepatic metastasis after surgical resection treated by S-1. and gemcitabine combination chemotherapy. A 59-year-old woman was diagnosed as locoregionally advanced pancreas head cancer without metastatic disease. Pancreatoduodenectomy with regional lymph node dissection was performed after preoperative chemoradiotherapy. Pathological examination revealed a poorly differentiated adenocarcinoma. A solitary hepatic metastasis was detected by CT imaging one year after the surgery. The patient received 35 courses of S-1. and gemcitabine combination therapy. The metastatic tumor was disappeared, and serum CEA decreased to a normal level. S-1 and gemcitabine combination therapy is not only effective but also well tolerated and safe. This combination therapy should be considered one of selective choices for advanced or metastatic pancreatic cancer.

Original languageEnglish
Pages (from-to)2419-2421
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Volume36
Issue number12
Publication statusPublished - Nov 2009

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A long-term survival case of pancreatic cancer with hepatic metastasis after pancreaticoduodenectomy successfully treated by S-1 and gemcitabine combination chemotherapy'. Together they form a unique fingerprint.

Cite this